JMP reiterates Critical Therapeutics at market outperform

JMP Securities analyst Adam Cutler reiterated Critical Therapeutics, Inc. at market outperform on news of positive data from the phase 1/ 2 study of Zyflo IV in asthma. All 60 patients completed the trial, with data indicating that Zyflo was well-tolerated at all doses tested. According to the analyst, the Food and Drug Administration may require additional testing since the most recent study may not reflect the drug's use in the emergency room. Shares of the Lexington, Mass.-based biopharmaceutical company were up 2 cents, or 0.52%, at $3.84, on volume of 23,892 shares versus the three-month running average of 36,180 shares. (Nasdaq: CRTX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.